**Qurient is looking for a motivated scientist who will lead all biology/pharmacology innovation for the first-in-class drug development**

**Qurient** is a clinical-stage biopharmaceutical company listed on the Korea Exchange (Ticker: 115180). Qurient mainly focuses on development of novel therapeutics from discovery to human proof of concept stages through a virtual R&D platform with vast network of research institutes around world. Qurient currently has three programs in clinical development: **Q301**, a topical leukotriene inhibitor for atopic dermatitis, **telacebec (Q203)**, a first-in-class orally available cytochrome bc1 inhibitor for tuberculosis, and **Q702**, Axl/Mer/CSF1R RTK inhibitor for immuno-oncology indications. Qurient recently nominated **Q901**, a selective CDK7 inhibitor for solid tumors. Qurient has access to multiple novel discovery programs under strategic alliance with Lead Discovery Center/Max Planck Innovation in Germany. Qurient is pursuing new business model to have new programs form a new single asset company, such that research efficiency as well as return to the participants can be maximized. Qurient looks for motivated scientists who can enjoy cutting edge science and gain significant return on the way.

**Director, Biology and Pharmacology**

**Role and Responsibilities**

* Lead the biology/pharmacology team to bring discovery programs to candidate nomination
* Lead in-licensing of research programs from network of research institutes
* Lead collaborations with research institutes
* Participate in the R&D leadership team to set up R&D strategy
* Support business development and investor relationship activities
* R&Rs can be expanded to executive functions based on performance or qualification

**Qualifications**

* Doctoral degree in biological sciences with industry experiences
* Excellent communication skills and fluency in English
* Passion for new sciences